Therapeutic Asset Ratings

622 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
gsk2110183 Breast Cancer	Laekna Limited	P3	CCC (50)
hlx11 Breast Cancer	Shanghai Henlius Biotech	P3	CCC (50)
hs627 Breast Cancer	BioRay Pharmaceutical Co., Ltd.	P3	CCC (50)
Investigational Drug: Recombinant Anti-Her2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates For Breast Cancer	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.	P3	CCC (50)
js105 Breast Cancer	Risen (Suzhou) Pharma Tech Co., Ltd.	P3	CCC (50)
Lornoxicam Breast Cancer	Fudan University	P3	CCC (50)
Nuvastatic Breast Cancer	Natureceuticals Sdn Bhd	P3	CCC (50)
Oxybutynin Breast Cancer	Reinier de Graaf Groep	P3	CCC (50)
PF-07850327 Breast Cancer	Pfizer	P3	CCC (50)
tol2506 Breast Cancer	Tolmar Inc.	P3	CCC (50)
[99mtc]tc-db8 Breast Cancer	Tomsk National Research Medical Center of the Russian Academy of Sciences	P2	CCC (50)
Adebelimab Breast Cancer	Shandong Suncadia Medicine Co., Ltd.	P2	CCC (50)
ANTI-HER2 BSAB KN026 Breast Cancer	CSPC Megalith Biopharmaceutical Co.,Ltd.	P2	CCC (50)
Aprotinin Breast Cancer	Sun Yat-sen University	P2	CCC (50)
Axatilimab Breast Cancer	Stephen Shiao	P2	CCC (50)
bl0175 Breast Cancer	Shanghai Best-Link Bioscience, LLC	P2	CCC (50)
Canagliflozin Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (50)
Dostarlimab Breast Cancer	University of Washington	P2	CCC (50)
Fam-Trastuzumab Deruxtecan-Nxki Breast Cancer	Memorial Sloan Kettering Cancer Center	P2	CCC (50)
Iodixanol Breast Cancer	Brian Henick, MD	P2	CCC (50)
Ivonescimab Breast Cancer	Akeso	P2	CCC (50)
Ladiratuzumab Vedotin Breast Cancer	Hoffmann-La Roche	P2	CCC (50)
N-Acetyl-L-Cysteine Breast Cancer	Fudan University	P2	CCC (50)
Pegylated Interferon Alpha2A Breast Cancer	BriaCell Therapeutics Corporation	P2	CCC (50)
Pemigatinib Breast Cancer	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (50)

Showing 226 to 250 of 622 assets

PreviousPage 10 of 25Next